Succeeder(SH:688338)2021-10-26 16:00Financial Performance - The company's revenue for Q3 2021 was ¥53,462,283.47, representing a year-on-year increase of 2.93%[5] - Net profit attributable to shareholders was ¥25,315,625.17, up 67.52% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses was ¥21,889,090.45, an increase of 44.98% year-on-year[5] - Basic earnings per share were ¥0.31, reflecting a 93.79% increase compared to the previous year[6] - Total operating revenue for the first three quarters of 2021 reached ¥164,152,824.88, an increase of 8.4% compared to ¥151,135,602.87 in the same period of 2020[21] - Net profit for the first three quarters of 2021 was ¥67,039,891.03, up 66.9% from ¥40,158,932.04 in the previous year[22] - Earnings per share for the period was ¥0.82, compared to ¥0.57 in the same period last year, reflecting a 43.9% increase[22] - The company reported a total profit of ¥76,696,181.38 for the first three quarters, an increase of 62.1% from ¥47,335,283.68 in the same period of 2020[22] Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date was ¥58,050,438.23, showing a significant increase of 97.07%[5] - Operating cash inflow for Q3 2021 was CNY 214,679,023.96, an increase from CNY 191,503,072.86 in Q3 2020, representing a growth of approximately 12.1%[25] - Net cash flow from operating activities was CNY 58,050,438.23, significantly up from CNY 29,456,685.13 in the same period last year, indicating a year-over-year increase of about 96.5%[25] - Cash outflow from investment activities totaled CNY 1,271,040.70, a decrease from CNY 31,059,154.12 in Q3 2020, reflecting a reduction of approximately 95.9%[26] - Net cash flow from financing activities was negative CNY 35,431,435.32, compared to a positive CNY 912,623,588.23 in Q3 2020, showing a significant decline[26] - The ending balance of cash and cash equivalents was CNY 1,283,998,568.75, up from CNY 1,231,494,688.84 at the end of Q3 2020, marking an increase of about 4.3%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,441,027,266.93, a growth of 2.82% from the end of the previous year[6] - Total assets reached CNY 1.44 billion, an increase from CNY 1.40 billion at the end of 2020[18] - Total liabilities increased to ¥50,494,551.93 from ¥45,312,936.30, marking an increase of 11.9%[19] - Total equity attributable to shareholders rose to ¥1,390,532,715.00 from ¥1,356,152,023.97, an increase of 2.5%[19] - Current liabilities totaled 43,743,257.64, with a significant portion attributed to employee compensation and taxes payable[30] - Non-current liabilities rose to 5,294,926.81, primarily due to lease liabilities of 3,725,248.15[30] Research and Development - Research and development expenses totaled ¥3,546,751.06, accounting for 6.63% of revenue, which is an increase of 0.08 percentage points[6] - Research and development expenses for the first three quarters were ¥11,887,089.91, up from ¥10,203,118.14, indicating a growth of 16.5%[21] - The company obtained 1 new invention patent during the reporting period, and 5 new in vitro diagnostic reagent products completed the registration assessment phase[15] Government Support and Subsidies - The company received government subsidies amounting to ¥4,035,210.62 during the reporting period, contributing to other income[9] Market and Future Plans - The company plans to continue expanding its market presence and investing in new technologies, although detailed figures and timelines were not provided in the report[26] - The company is advancing the construction of its integrated production and R&D project for thrombosis and hemostasis products, having obtained the necessary planning permits[15] Financial Reporting Changes - The company has implemented new leasing standards starting in 2021, which may affect future financial reporting and cash flow management[26] - The earnings report was officially announced on October 27, 2021, by the board of directors[32]